Eşkazan, A. E., & Soysal, T. (2013). Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia. Galenos Publishing.
Styl ChicagoEşkazan, Ahmet Emre, a Teoman Soysal. Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients With Chronic Myeloid Leukemia. Galenos Publishing, 2013.
Citace podle MLAEşkazan, Ahmet Emre, a Teoman Soysal. Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients With Chronic Myeloid Leukemia. Galenos Publishing, 2013.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..